Tag Archives: Blockbuster

Will NFL ever see three-team trade again? Here are two blockbuster deals including Kirk Cousins, Justin Fields – CBS Sports

  1. Will NFL ever see three-team trade again? Here are two blockbuster deals including Kirk Cousins, Justin Fields CBS Sports
  2. How will Lakers manage LeBron in his 21st season? + Giannis speaks out on Lillard trade | NBA Today ESPN
  3. Former All-Star interested in joining Milwaukee Bucks after Lillard trade Behind the Buck Pass
  4. “I think it’s dope, I’m happy for him” – CJ McCollum reacts to Damian Lillard trade Basketball Network
  5. Insider Believes Lakers Must Be Taken Seriously As Jrue Holiday Trade Destination with a Caveat Sports Illustrated
  6. View Full Coverage on Google News

Read original article here

Sunny Deol Talks ‘Gadar 2’ Blockbuster Success: ‘It’s Become an Indian Marvel Hero’ (EXCLUSIVE) – Variety

  1. Sunny Deol Talks ‘Gadar 2’ Blockbuster Success: ‘It’s Become an Indian Marvel Hero’ (EXCLUSIVE) Variety
  2. Beautiful to see world celebrating ‘Gadar 2’: Sunny Deol at London screening IndiaTimes
  3. Gadar 2 leaves Pathaan behind with its 10-day collection despite fewer screens Hindustan Times
  4. Top 5: Rajni And Sunny Shake The Industry.. Greatandhra
  5. Dulquer Salmaan applauds Gadar 2’s success, praises Sunny Deol’s dedication despite ‘aches and pains’ The Indian Express
  6. View Full Coverage on Google News

Read original article here

‘Barbie’ Breaks $500 Million At U.S. Box Office—Further Cementing Itself As Summer’s Blockbuster – Forbes

  1. ‘Barbie’ Breaks $500 Million At U.S. Box Office—Further Cementing Itself As Summer’s Blockbuster Forbes
  2. Box Office: ‘Barbie’ and ‘Oppenheimer’ Triumphant Again, ‘Last Voyage of the Demeter’ Capsizes Yahoo Entertainment
  3. Barbie hits a billion, Alia Bhatt’s Hollywood debut: Check out the newsmakers of the week IndiaTimes
  4. Barbie’s Greta Gerwig becomes highest-grossing female director of all time at the domestic box office Yahoo Entertainment
  5. ‘Frozen’ Fever Is Officially Over Thanks to ‘Barbie’ Inside the Magic
  6. View Full Coverage on Google News

Read original article here

San Diego Padres rumors: Houston Astros tried to make blockbuster deal at MLB trade deadline – Friars on Base

  1. San Diego Padres rumors: Houston Astros tried to make blockbuster deal at MLB trade deadline Friars on Base
  2. Ohtani remains w/ Angels, Astros acquire Verlander, Dodgers & Yankees add pitching | MLB | THE HERD The Herd with Colin Cowherd
  3. Astros owner Jim Crane has never ‘seen anything like this’ Justin Verlander trade New York Post
  4. 2 former Mets they just traded bound for a deep playoff run, 2 who won’t even make the postseason Rising Apple
  5. Checkout what Astros owner Jim Crane had to say about the Mets trading Justin Verlander | SNY SNY
  6. View Full Coverage on Google News

Read original article here

How ‘Barbie’ Went Outside The Box On Her Long Journey To Become A Blockbuster: Global Opening Now At $356M – Box Office – Deadline

  1. How ‘Barbie’ Went Outside The Box On Her Long Journey To Become A Blockbuster: Global Opening Now At $356M – Box Office Deadline
  2. ‘Barbie’ Made HOW Much at the Box Office?! AOL
  3. Opinion: ‘Barbie’ breaks box-office records while crushing right-wing outrage CNN
  4. ‘Barbenheimer’ Even Bigger Than Expected: ‘Barbie’ Soars to $162 Million, ‘Oppenheimer’ Jumps to $82 Million Variety
  5. Oppenheimer and Barbie’s Opening Weekend Results: Here’s How Much They Made Startefacts
  6. View Full Coverage on Google News

Read original article here

‘Tetris’ Review: Taron Egerton Brings Home the Original Blockbuster in Video Game History Lesson – Variety

  1. ‘Tetris’ Review: Taron Egerton Brings Home the Original Blockbuster in Video Game History Lesson Variety
  2. ‘Tetris’ Review: Taron Egerton in a Compelling Video Game Origin Story That Could Have Been More Hollywood Reporter
  3. ‘Tetris’ Review: Taron Egerton In Sensational Video Game Origin Story That Plays Like A Nail-Biting Cold War Spy Thriller – SXSW Deadline
  4. ‘Tetris’ review: This video game-inspired adventure is a winner Mashable
  5. Tetris Review: Some Pieces Are Missing In Well-Made But Standard Dramedy Screen Rant
  6. View Full Coverage on Google News

Read original article here

Rich Eisen Reacts to the Panthers’ Blockbuster Trade with the Bears to Get the #1 Pick in NFL Draft – The Rich Eisen Show

  1. Rich Eisen Reacts to the Panthers’ Blockbuster Trade with the Bears to Get the #1 Pick in NFL Draft The Rich Eisen Show
  2. Rich Eisen’s Top 5 Wildest Lamar Jackson Destinations | The Rich Eisen Show The Rich Eisen Show
  3. PFT’s Mike Florio: Don’t Be Shocked If Raiders Pursue Baker Mayfield | The Rich Eisen Show The Rich Eisen Show
  4. What’s More Likely: Rich Eisen on the Jets, Giants, Rams, 49ers, Bills, Steelers, Patriots & More The Rich Eisen Show
  5. Maurice Jones-Drew: Ravens Would Be Foolish to Part Ways with Lamar Jackson | The Rich Eisen Show The Rich Eisen Show
  6. View Full Coverage on Google News

Read original article here

What it’s like to take the blockbuster drugs Ozempic and Wegovy, from severe side effects to losing 50 pounds

For the two months Carey Yazeed took Ozempic, the drug worked as intended. Yazeed has type 2 diabetes, and the weekly injection lowered her blood sugar levels. But it also brought side effects she considered unbearable, including vomiting, fatigue, headaches and stomach cramps.

Five weeks into taking the medication, Yazeed said, she found herself unable to move off the bathroom floor.

“I had vomited so much that I didn’t have the energy to get up and I was basically lying in it,” she said. “I couldn’t even raise my head to vomit in the commode. It was so bad.”

Dr. Carey Yazeed. (Courtesy Carey Yazeed.)

The severe effects Yazeed faced aren’t common, but people’s experiences taking Ozempic and its sister drug, Wegovy, can vary widely — from substantial weight loss and minimal discomfort on one end of the spectrum to extreme effects on the other.

NBC News spoke to 10 people about their experiences taking these blockbuster drugs, both of which are forms of semaglutide. They’re designed to mimic a hormone that signals to the brain when a person is full and promotes the release of insulin, a hormone that stops blood sugar from getting too high. In turn, the medications can lower blood sugar levels and suppress appetites.

They have soared in popularity over the last year, in part from social media attention and billionaires like Elon Musk touting the drugs’ weight loss effects.

Prescriptions for Ozempic tripled from 2021 to 2022, according to data from the prescription drug discount company SingleCare, which has more than 5 million members. Last year, high demand and global supply constraints gave rise to shortages of the medications. The FDA reported a Wegovy shortage in March 2022, followed by an Ozempic shortage in August.

Several people interviewed said the benefits they got from the drugs outweighed the side effects.

“It just feels lighter moving around. My clothes fit so much better and more comfortably,” said Stacey Bollinger, an account director in Maryland, who reported losing 52 pounds since starting Wegovy. “Something as simple as bending over to tie my shoe is so much easier.”

Stacey Bollinger. (Courtesy Stacey Bollinger)

Some people said they felt fine on the medications. But Yazeed and a couple of others described side effects that forced them to stop taking the drugs or question whether they could stay on them long term.

Obesity medicine experts who prescribe Ozempic and Wegovy said the drugs can transform patients’ lives and health. The weight loss effects can enable patients to do activities they couldn’t do previously, like chase after grandchildren or find clothes that fit at mainstream stores. Semaglutide can also address health issues linked to obesity and diabetes, such as an elevated risk of heart attacks or stroke.

“By treating obesity, you’re effectively potentially treating over 200 other obesity-related or weight-related diseases,” said Dr. Ania Jastreboff, an associate professor of medicine at the Yale School of Medicine. Jastreboff serves on the scientific advisory board of Novo Nordisk, which makes Ozempic and Wegovy.

Accounts of dramatic weight loss

The Food and Drug Administration approved Ozempic for people with type 2 diabetes in 2017, then Wegovy — the same drug, which goes up to higher dosage — in 2021 for weight loss in adults with obesity or those who are overweight and have least one weight-related health condition, such as high blood pressure or cholesterol. Ozempic is not approved for weight loss, but doctors sometimes prescribe it off-label for that purpose.

Most people who took Ozempic or Wegovy said it curbed their hunger and reduced cravings for unhealthy food. Bollinger and Randi Lee Harper, a software developer in the Seattle area, each reported losing more than 50 pounds.

Harper took Ozempic off-label for weight loss from May until November (she paused while moving to Washington state but plans to start again). She said she still enjoyed her favorite foods — like truffle mac n’ cheese and Sour Patch Kids candy — but her portions were smaller.

“You don’t realize how much your life is centered around food when you’re overweight until you’re on a diet that just lets you not think about it so much, like on Ozempic,” Harper said.

For the most part, she added, she reacted well to the medication, though sometimes she burped if she ate too much — a fairly common side effect.

As for Bollinger, she said that in addition to her weight loss, her average blood sugar levels have dropped to a point where she’s no longer pre-diabetic.

A study of more than 1,000 people with type 2 diabetes found that semaglutide was more effective than insulin at lowering blood sugar. The participants had not seen results from other antidiabetic drugs, which they continued to take during the trial. In another study of nearly 2,000 overweight or obese adults without diabetes, people taking semaglutide lost an average of 34 pounds in less than 16 weeks, compared to 6 pounds among those receiving a placebo.

Dr. C. Nicole Swiner, a family medicine doctor in Durham, North Carolina, said she started taking Wegovy in 2021 after seeing how much it helped her patients. She has lost 30 pounds since then, she said.

“Because I’m not starving, I can actually stop and make a smarter decision [rather] than, ‘Oh my God, I’m ravenous. Let me grab whatever’s in the office kitchen,’ which is usually junk,” Swiner said.

C. Nicole Swiner. (Chris Charles)

On Wegovy, she added, she eats less overall and has swapped sugary treats like cookies or muffins for healthier alternatives like yogurt or fruit.

For Yazeed, weight loss was not the reason she went on Ozempic, nor was it a goal. But on the drug, she said, she had to force herself to eat and often couldn’t stomach anything beyond a protein shake in the morning. On a good day, she might also tolerate some chicken broth.

She lost 10 pounds in two months, going from a size 12 to an 8 or 10.

Patients who stop taking the drugs often regain weight

Like many drugs, the effects of semaglutide stop when patients go off of it, so some people regain weight. Experts said they consider Ozempic and Wegovy to be lifelong medications.

“Data from our clinical trials for Wegovy showed that, not unexpectedly, patients experience weight regain once they stop taking the medication,” Novo Nordisk told NBC News in a statement.

“This supports the belief that obesity is a chronic disease that requires long-term management, much like high blood pressure or high cholesterol, for which most patients remain on therapy long term,” the company added.

Ebony Wiggins, who has type 2 diabetes, said she has gained back about 15 pounds of the 25 she lost last year while taking Ozempic.

Artemis Bayandor, who lives in Naperville, Illinois, said she weighs more now than when she took Wegovy: Within one month of stopping the medication, she gained back the 15 pounds she had lost on the drug, she said, plus an extra 10 over the next six months.

“For the first week I was OK, and for the second week I went right back to all of the cravings, but worse,” Bayandor said.

Side effects put some people off the medications

Courtney Hamilton didn’t made it more than a month on Ozempic, which her doctor prescribed off-label because Hamilton has type 1 diabetes, not type 2.

Her nausea got so bad that she could barely eat, Hamilton said, and the foods she could tolerate weren’t particularly healthy.

“Ironically, it made me stick to very starchy, carby foods like potatoes because they’re very bland. I ate a lot of that and a lot of plain toast,” she said.

People typically start with a low dose of Ozempic or Wegovy, then ramp up to reduce side effects. Dr. Fatima Cody Stanford, an assistant professor of medicine at Massachusetts General Hospital, said some severe effects may be the result of raising that dosage too quickly.

“If the patient’s saying, ‘Oh gosh, I’m sick. I can’t even go to work, I’m vomiting all day,’ it’s probably the dose is just not an appropriate dose for them,” Stanford said.

In clinical trials, 73% of adults taking the highest dose of Wegovy reported gastrointestinal issues. Nausea, diarrhea, vomiting, constipation and stomach pain are most common. Some people have reported more serious, albeit rare, side effects like pancreatitis and kidney failure.

Novo Nordisk said patients experiencing nausea as a side effect should contact their health care provider for guidance about ways to manage it.

Jastreboff said she encourages her patients to consume smaller, more frequent meals, not eat past the point of fullness, and monitor which foods exacerbate their symptoms. Most side effects occur as people are increasing their dosage, then subside once they reach the maintenance phase, she added.

Megan Cornelius, who has been taking Ozempic off-label for type 1 diabetes for several years, said she was nauseous and fatigued at first but those effects faded over time.

“As long as I can continue to take it, I probably will,” Cornelius said.

Eric Joiner Jr. (Cortesía de Eric Joiner Jr.)

For Eric Joiner Jr., a former type 2 diabetic, Ozempic hasn’t done anything beyond its intended effect: improve his kidney function — an off-label application of the drug. Joiner developed chronic kidney disease as a byproduct of his diabetes.

He hasn’t experienced side effects or weight loss from Ozempic, he said, but he recognizes that isn’t true for everyone.

“At the end of the day, it’s a very personal thing,” he said. “Your biology is different than mine.”

This story originally appeared on NBCNews.com.

This article was originally published on TODAY.com

Read original article here

Stock futures fall ahead of blockbuster week

U.S. stock futures moved lower ahead of the open Monday as investors await a blockbuster week that includes the latest Fed meeting, a flurry of heavyweight earnings reports, and jobs data.

Futures tied to the S&P 500 (^GSPC) down 1%, while futures on the Dow Jones Industrial Average (^DJI) lost 0.7%. Contracts on the technology-heavy Nasdaq Composite (^IXIC) declined by roughly 1.3%

The yield on the benchmark 10-year U.S. Treasury note ticked up to 3.557% on Monday morning. The dollar index ticked down 0.08% to $101.85.

Stocks closed a winning week Friday following data that pointed to stronger-than-expected U.S. economic growth, while Tesla shares jumped over 10% after reporting a record quarterly revenue.

All the major market averages finished higher for the week, with the S&P 500 gaining 2.5%, the Dow Jones Industrial average ending up 1.8% and the technology-heavy Nasdaq Composite climbing north of 4%.

The Commerce Department said Friday the personal consumption expenditures price index, excluding energy and food, showed prices rose 4.4% from a year earlier. Friday’s report came in a day after the government reported a better-than-expected 2.9% gain in gross domestic product for the fourth quarter, boosting hopes that the Federal Reserve may head toward the elusive “soft landing” scenario.

Fed officials will be meeting in Washington, D.C., Tuesday and Wednesday. The meeting will wrap up with Fed Chair Jerome Powell holding a press conference Wednesday afternoon as he offers signs of the central bank’s path forward on rate hikes.

“The FOMC’s work is not yet done, even if the recent declines in inflation and wage growth give it more time to assess the effects of past policy actions. A key challenge for the FOMC will be to execute its transition to smaller rate hikes without furthering expectations that an end to its hiking cycle is imminent,” the team at Barclays wrote.

At the end of week, investors will get another clue of the Fed’s path as the government’s January jobs report is set to be released Friday morning. Economists surveyed by Bloomberg expect 185,000 jobs were added to the economy last month, a slowdown from the gain of 223,000 jobs in December.

Chair of the Board of Governors of the Federal Reserve System Jerome H. Powell participates in a panel during a Central Bank Symposium at the Grand Hotel in Stockholm, Sweden, January 10, 2023. TT News Agency/Claudio Bresciani/via REUTERS ATTENTION EDITORS – THIS IMAGE WAS PROVIDED BY A THIRD PARTY. SWEDEN OUT. NO COMMERCIAL OR EDITORIAL SALES IN SWEDEN.

Meanwhile, it’s the biggest week of the fourth-quarter earnings season, with Big Tech results taking the spotlight amid thousands of layoffs in the industry. Despite the already announced job cuts, the tech companies’ are in part to blame for the disaster, Yahoo Finance’s Dan Howley writes.

The heavy earnings slate includes reports from tech heavyweights Amazon (AMZN), Apple (AAPL), Alphabet (GOOG), and Meta Platforms (META).

Elsewhere in markets, shares of Lucid (LCID) advanced more than 4% before the opening bell. On Friday, the electric-vehicle maker surged more than 88% following speculation that a Saudi Arabia Public Investment Fund (PIF) is considering buying its remaining stake in the company.

Alibaba (BABA) shares fell 5% in premarket trading on Monday after reports that the Chinese e-commerce site is moving its headquarters out of the country, suggesting the new campus could be in Singapore, according to reports.

SoFi Technologies (SOFI) shares rose 7% Monday morning after the digital financial services company posted an upbeat earnings guidance for the full year ahead. SoFi reported total deposits increased 46% on a sequential basis. The company expects $40 million to $45 million in adjusted EBITDA for the first quarter and for the full year, and anticipates to see $260 million to $280 million.

In the cryptocurrency market, Bitcoin (BTC-USD) has fallen over 1% to $23,168 over the last 24 hours, according to CoinMarketCap. However, the largest token is on its way for its best January since 2013, per Bloomberg, on bets that monetary tightening and the sector’s crisis are both receding.

Dani Romero is a reporter for Yahoo Finance. Follow her on Twitter @daniromerotv

Click here for the latest stock market news and in-depth analysis, including events that move stocks

Read the latest financial and business news from Yahoo Finance

Download the Yahoo Finance app for Apple or Android

Follow Yahoo Finance on Twitter, Facebook, Instagram, Flipboard, LinkedIn, and YouTube



Read original article here

Square Enix Blockbuster Touts Bogus Accolades In Launch Trailer

Screenshot: Square Enix

Everything about the leadup to the release of Forspoken, Square Enix’s big new open-world action RPG, has been a lowkey mess. But you wouldn’t know that from the launch trailer which stays upbeat on the modern-day magical adventure by taking a bunch of words out of context and spinning them into deceitful accolades.

“This Forspoken launch trailer is kind of telling us that the game might not actually be that good and here’s how I know,” trailer editing aficionado Derek Lieu said in a TikTok video that blew up over the weekend. “The biggest red flag are these quotes which are either one word long or two words long.”

He proceeded to go through each phrase flashed on screen during it, found the original source it was from, and read the larger context aloud. In almost every instance the meaning was very different from the way the words were presented in the trailer, and not intended to be taken as unambiguous praise.

In one example, Square Enix lifted the word “Beautiful” from a December preview published over at Distractify. In context, however, the quote wasn’t saying that Forspoken was beautiful but that it had the “potential” to be a “beautiful story-driven game that will pull at your heartstrings with each new chapter.” It was, after all, a preview and not a review of the final game, though the site’s editor said she didn’t take issue with how the word was used.

“Square Enix did ask for permission to use the quote, and we did approve,” Distractify gaming editor, Sara Belcher, told Kotaku in an email. “In our actual review, I do refer to the game as ‘beautiful’ (that was my opinion of the game’s world since the preview, which is why I didn’t personally feel the quote felt out of context). We do not charge for the use of quotes in promotional materials.”

In another example, the Final Fantasy maker quotes the word “impressive” from Game Informer. The only problem is that the word in question doesn’t even come from a hands-on preview, but from a news write-up of a gameplay trailer from a Sony State of Play. “Frey’s traversal abilities are impressive, allowing for fast movement in and out of combat, both in aerial and aquatic situations,” it reads.

To recap then, Forspoken’s newest trailer included a truncated quote of someone describing one of its older trailers. Game Informer’s actual review gave the game a 7.5 out of 10. It did not include the word impressive, instead describing main protagonist Frey’s overall adventure as “[not] without its highlights.”

Game Informer did not immediately respond to a request for comment. 

Lieu told Kotaku that the intent of the video wasn’t to claim that he thinks the game is or will be bad, but rather that the misleading framing heavily implies that Square Enix wasn’t confident enough in the game to let it stand on its own without the bogus accolades.

“They could be entirely wrong taking this approach and the game is actually good, or has merits they could be focusing on instead of looking for quotes,” he said. “So I think it says more about the people in charge of marketing the game than it does the game itself.”

Companies relying on misleading quotes from critics and review outlets is nothing new. Sometimes they remove the original context. Sometimes they just search for any source, whether it’s reputable or not, that says your game is awesome. Almost always the accolades themselves are in giant fonts while the publications they’re pulled from are too small to read unless you’re taking time to analyze them in a TikTok video like Lieu.

As a point of comparison, he also shared two Forpsoken trailers that make the game look appealing without resorting to lies. The first was a trailer for the demo released last month. The second was a recut of an existing social media trailer that was repeatedly roasted online for its Joss Whedon-style fourth-wall-breaking dialogue.

“The real problem isn’t the narration at all, it’s that they don’t lean hard enough into the tone the narration should be selling and i know that because i proved it just now to be sure,” wrote Twitter user spellbang who took the same ingredients but remixed them in a way that looked much cooler while retaining the sensibility of the original.

The artistry behind making a good video game trailer aside, lying is bad and companies shouldn’t do that. It’s bad enough when a trailer full of pre-baked footage masks, say, how poorly a game actually runs. It’s even worse, though, when companies go out of their way to try and rope independent media outlets into their deceit. Publishers are supposed to get permission before using other people’s quotes in their marketing, and to be transparent about how they will be used.

Square Enix did not immediately respond to requests for comment.

               



Read original article here